Gao Ke, Ma Wen-Zhuo, Huck Scarlett, Li Bo-Lin, Zhang Li, Zhu Jiao, Li Tian, Zhou Dan
Department of Cardiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, South Kingstown, RI, United States.
Front Med (Lausanne). 2021 Nov 17;8:755705. doi: 10.3389/fmed.2021.755705. eCollection 2021.
Little is known about whether sarcopenia predicts incident depressive symptoms in older adults. Using the nationally representative data from the China Health and Retirement Longitudinal Study (CHARLS), we conducted cross-sectional and longitudinal analyses to estimate the association between sarcopenia and depressive symptoms among older adults. The sample comprised 7,706 participants aged at least 60 years (50.6% women; mean age 68.0 ± 6.5) from the CHARLS 2015. Based on the Asian Working Group for Sarcopenia 2019 (AWGS 2019) criteria, sarcopenia status was classified into three types: no-sarcopenia, possible sarcopenia, and sarcopenia. Depressive symptoms were assessed using the validated 10-items of the Center for Epidemiologic Studies Depression Scale. A cross-sectional analysis was used to examine the relationship between sarcopenia status and depressive symptoms. A total of 4,652 participants without depressive symptoms were recruited from the same cohort in 2015 and were followed up in 2018. Cox proportional hazards regression models were conducted to examine the effect of sarcopenia status on subsequent depressive symptoms with the report of hazard ratio (HR). The prevalence of depressive symptoms in total populations, no-sarcopenia, possible sarcopenia, and sarcopenia individuals were 27.1% (2085/7706), 21.5% (927/4310), 33.6% (882/2627), and 35.9% (276/769), respectively. Both possible sarcopenia (OR: 1.75, 95% CI: 1.46-2.10) and sarcopenia (OR: 1.64, 95% CI: 1.23-2.19) were positively associated with higher odds of depressive symptoms (all < 0.01). During the 3.7 years of follow-up, 956 cases (20.6%) with incident depressive symptoms were identified. In the longitudinal analysis, individuals with the diagnosed possible sarcopenia (HR: 1.27, 95% CI: 1.01-1.58) and sarcopenia participants (HR: 1.49, 95% CI: 1.06-2.09) were more likely to have new onset depressive symptoms than no-sarcopenia peers. Both possible sarcopenia and sarcopenia, assessed using the AWGS 2019 criteria, were independent predictors for the occurrence of depressive symptoms among Chinese older adults. Our findings provided new evidence supporting the longitudinal connection between sarcopenia and mental health problems, it also provides further justification for timely identification and management of both possible sarcopenia and sarcopenia as part of comprehensive strategies to fight against depressive symptoms.
关于肌肉减少症是否能预测老年人出现抑郁症状,目前所知甚少。利用中国健康与养老追踪调查(CHARLS)具有全国代表性的数据,我们进行了横断面分析和纵向分析,以评估老年人中肌肉减少症与抑郁症状之间的关联。样本包括来自CHARLS 2015的7706名年龄至少60岁的参与者(50.6%为女性;平均年龄68.0±6.5岁)。根据2019年亚洲肌肉减少症工作组(AWGS 2019)的标准,肌肉减少症状态分为三种类型:无肌肉减少症、可能存在肌肉减少症和肌肉减少症。使用经过验证的10项流行病学研究中心抑郁量表来评估抑郁症状。横断面分析用于检验肌肉减少症状态与抑郁症状之间的关系。2015年从同一队列中招募了4652名无抑郁症状的参与者,并在2018年进行随访。采用Cox比例风险回归模型,以风险比(HR)报告来检验肌肉减少症状态对随后抑郁症状的影响。总人群、无肌肉减少症、可能存在肌肉减少症和肌肉减少症个体中抑郁症状的患病率分别为27.1%(2085/7706)、21.5%(927/4310)、33.6%(882/2627)和35.9%(276/769)。可能存在肌肉减少症(OR:1.75,95%CI:1.46 - 2.10)和肌肉减少症(OR:1.64,95%CI:1.23 - 2.19)均与抑郁症状的较高发生率呈正相关(均P<0.01)。在3.7年的随访期间,共识别出956例(20.6%)出现抑郁症状的病例。在纵向分析中,被诊断为可能存在肌肉减少症的个体(HR:1.27,95%CI:1.01 - 1.58)和肌肉减少症参与者(HR:1.49,95%CI:1.06 - 2.09)比无肌肉减少症的同龄人更有可能出现新发抑郁症状。使用AWGS 2019标准评估的可能存在肌肉减少症和肌肉减少症均是中国老年人抑郁症状发生的独立预测因素。我们的研究结果提供了新的证据,支持肌肉减少症与心理健康问题之间的纵向联系,也为及时识别和管理可能存在肌肉减少症和肌肉减少症提供了进一步的理由,作为对抗抑郁症状综合策略的一部分。